Testing an Anti-Inflammatory Drug for Heart Disease With TET2 Mutation
Treatments studied
Part of Blood & lymphatic, Heart & circulation, Immune system & allergy clinical trials.
This study tests whether a medication that blocks inflammation (called an IL-1 beta inhibitor) can reduce blood vessel inflammation in people with both heart disease and a specific genetic change in their blood cells (TET2 mutation). It aims to see if targeting this type of inflammation can help lower heart risks.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 or older.
- You must have coronary artery disease (like a past heart attack, a stent placed more than 6 months ago, or a high calcium score on a heart scan).
- Your blood must have a TET2 mutation (a specific genetic change found in some people's blood cells).
- You cannot currently take strong steroids or immune-suppressing medications by mouth or injection.
- You cannot have a current or past blood cancer or solid tumor.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests if the drug tofacitinib can help people whose heart inflammation from cancer immunotherapy (called ICI-related myocarditis) does not improve with steroids. If you have this condition, this study may offer a new treatment option.
This study looks at whether a comprehensive add-on treatment—starting with immune medicine and then a heart procedure when needed—can improve outcomes for people whose coronary artery disease is getting worse quickly. It focuses on cases where inflammation is likely driving new artery blockages or worsening chest pain.
This study tests whether a low-dose medicine called colchicine can reduce inflammation and slow down artery blockages in people who have a specific gene change (TET2) and have recently had a heart attack. The goal is to see if it helps prevent future heart problems.
This study tests two new medications, vunakizumab and ivarmacitinib, for people with active Takayasu's arteritis (TAK) that is not fully controlled by standard treatments. The goal is to see if these drugs are safe and effective for reducing disease activity.
This trial tests whether adding a targeted anti-inflammatory drug to standard care can prevent future heart attacks or strokes in people with high-risk chronic coronary artery disease. It is for people who have a moderate narrowing in a heart artery with a vulnerable plaque and signs of inflammation.
This study uses heart scans (MRI or nuclear imaging) to better understand inflammatory heart conditions. If you have a suspected inflammatory heart disease and are already scheduled for one of these scans, you may be able to join.
Hear when a new Vascular Inflammation trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.